Form 4: Crinetics Pharmaceuticals Executive Stephen F. Betz Reports Acquisition of Stock and Options
SEC Form 4 Filing
Stephen F. Betz, Chief Scientific Officer of Crinetics Pharmaceuticals, reports acquiring 43,000 shares of common stock and options to purchase 65,000 shares.
Summary
- On February 20, 2025, Stephen F. Betz, the Chief Scientific Officer of Crinetics Pharmaceuticals, acquired 43,000 shares of common stock.
- These shares were received as restricted stock units, vesting 25% annually starting March 15, 2026.
- Betz also acquired options to purchase 65,000 shares of common stock at an exercise price of $36.86.
- These options vest in 48 equal monthly installments from February 20, 2025, and expire on February 19, 2035.
- Following these transactions, Betz directly owns 114,358 shares of Crinetics Pharmaceuticals common stock and options for 65,000 shares.
Sentiment
Score: 6
Explanation: The sentiment is neutral to slightly positive. The acquisition of shares and options by an executive suggests confidence, but it's a routine transaction.
Positives
- The acquisition of stock and options by a key executive could be seen as a positive sign, indicating confidence in the company's future prospects.
Industry Context
Form 4 filings are standard disclosures required by the SEC to provide transparency into the transactions of company insiders. These filings are closely watched by investors to gauge management's sentiment and confidence in the company's performance.
Comparison to Industry Standards
- Stock option grants and restricted stock units are common forms of executive compensation in the pharmaceutical industry.
- The vesting schedules and exercise prices are generally aligned with industry norms to incentivize long-term performance and retention.
- Companies like Amgen, Gilead, and Vertex also utilize similar compensation structures for their executives.
Stakeholder Impact
- The transaction could have a minor positive impact on shareholder sentiment if viewed as a sign of executive confidence.
- Employees may see the executive's increased stake in the company as a positive indicator of future prospects.
Key Dates
| Date | Description |
|---|---|
| 02/20/2025 | Date of the transaction: acquisition of stock and options. |
| 02/20/2025 | Vesting commencement date for stock options. |
| 03/15/2026 | First vesting date for restricted stock units (25% annually). |
| 02/19/2035 | Expiration date for the stock options. |
| 02/24/2025 | Date of signature on the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.